Acasti Pharma, Inc. - (ACST): Price and Financial Metrics

Acasti Pharma, Inc. - (ACST): $0.50

-0.02 (-3.92%)

POWR Rating

Component Grades













ACST Stock Price Chart Interactive Chart >

Price chart for ACST

ACST Price/Volume Stats

Current price $0.50 52-week high $1.22
Prev. close $0.53 52-week low $0.17
Day low $0.50 Volume 7,499,400
Day high $0.53 Avg. volume 28,372,254
50-day MA $0.49 Dividend yield N/A
200-day MA $0.46 Market Cap 105.21M

Acasti Pharma, Inc. - (ACST) Company Bio

Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.

ACST Latest News Stream

Event/Time News Detail
Loading, please wait...

ACST Latest Social Stream

Loading social stream, please wait...

View Full ACST Social Stream

Latest ACST News From Around the Web

Below are the latest news stories about Acasti Pharma Inc that investors may wish to consider to help them evaluate ACST as an investment opportunity.

10 Best Biotech Penny Stocks to Buy Now

In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]

Yahoo | June 14, 2021

Heres Why Acasti Pharma Inc. (NASDAQ:ACST) is an Attractive Investment Right Now

The trading price of Acasti Pharma Inc. (NASDAQ:ACST) floating higher at last check on Monday, May 17, closing at $0.44, 0.92% higher than its previous close. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Traders who pay close attention to intraday price movement should know that Heres Why Acasti Pharma Inc. (NASDAQ:ACST) is an Attractive Investment Right Now Read More »

Stocks Register | May 17, 2021

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department indicating that, based upon the Companys non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 as of May 10, 2021, the Companys securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel.

BioSpace | May 16, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | May 13, 2021

ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Acasti Pharma Inc. (Acasti or the Company) (NasdaqGS: ACST) with Grace Therapeutics Inc., pursuant to which Acasti shareholders will end up owning only approximately 55% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the mer

Business Wire | May 12, 2021

Read More 'ACST' Stories Here

ACST Price Returns

1-mo -2.44%
3-mo -29.58%
6-mo 100.00%
1-year -31.51%
3-year -33.33%
5-year -65.99%
YTD 53.85%
2020 -86.73%
2019 195.18%
2018 -11.70%
2017 -24.80%
2016 -50.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7584 seconds.